Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPGB vs Dexmedetomidine in Trans-nasal Endoscopic Pituitary Surgery
NCT06639659Active, not recruiting
- Sponsor
- Zagazig University
- Start
- Oct 2024
- Primary completion
- Oct 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of dexmedetomidine in pituitary neoplasm and postoperative pain (3 arms), sponsored by Zagazig University. Primary endpoints: Visual Analog Scale for Postoperative Pain at 24 hours and Average Category Scale for Surgical Field at 5 hours. Started Oct 2024; status: active, not recruiting.
02
Drugs
dexmedetomidine
03
Conditions
pituitary neoplasmpostoperative pain
Beyond the preview
Go deeper on NCT06639659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06639659.